"
Team:Potsdam Bioware
From 2012.igem.org
(→Project Description) |
|||
| Line 6: | Line 6: | ||
| - | + | <html> | |
| - | + | <div id="clustrmaps-widget"></div><script type="text/javascript">var _clustrmaps = {'url' : 'https://2012.igem.org/Team:Potsdam_Bioware', 'user' : 1035150, 'server' : '4', 'id' : 'clustrmaps-widget', 'version' : 1, 'date' : '2012-08-08', 'lang' : 'en', 'corners' : 'square' };(function (){ var s = document.createElement('script'); s.type = 'text/javascript'; s.async = true; s.src = 'http://www4.clustrmaps.com/counter/map.js'; var x = document.getElementsByTagName('script')[0]; x.parentNode.insertBefore(s, x);})();</script><noscript><a href="http://www4.clustrmaps.com/user/3d4fcb8e"><img src="http://www4.clustrmaps.com/stats/maps-no_clusters/2012.igem.org-Team-Potsdam_Bioware-thumb.jpg" alt="Locations of visitors to this page" /></a></noscript> | |
| + | </html> | ||
<!-- *** What falls between these lines is the Alert Box! You can remove it from your pages once you have read and understood the alert *** | <!-- *** What falls between these lines is the Alert Box! You can remove it from your pages once you have read and understood the alert *** | ||
Revision as of 20:36, 8 August 2012
Direct Antibody Identification, Maturation and Production in CHO-Cells
Project Description
Antibodies are versatile molecules for research and therapy and they are currently revolutionizing the market of biopharmaceuticals. To date, antibodies are generated in a laborious and time consuming manner. Either animal immunization followed by hybridoma technology or phage display is used to identify desired genes, which then need to be transferred to a production cell line such as CHO. We designed a streamlined workflow that incorporates all steps of antibody generation in CHO cells. Our plan is to stably transfect an antibody-fragment library in CHO cells. Antibody maturation is mimicked by further diversifying this library using the enzyme Activation-Induced cytidine Deaminase (AID), which is known to induce somatic hypermutation. Next, we plan to test and deploy a versatile and continuous viral selection system for clones producing the desired antibodies. Finally, we will try to employ a genetic switch to go from surface expression to soluble production of antibodies.
| Home | Team | Official Team Profile | Project | Parts Submitted to the Registry | Modeling | Notebook | Safety | Attributions |
|---|
